ストックスクリーナーアプリを入手
16.58
0.06%
0.010
アフターアワーズ：
16.59
0.01
+0.06%
前日終値:
$16.57
開ける：
$16.54
24時間の取引高:
2.34M
Relative Volume:
0.80
時価総額：
$52.39B
収益：
$29.91B
当期純損益:
$1.30B
株価収益率:
40.88
EPS:
0.4056
ネットキャッシュフロー:
$3.49B
1週間 パフォーマンス:
+0.97%
1か月 パフォーマンス:
-6.96%
6か月 パフォーマンス:
+17.67%
1年 パフォーマンス:
+16.51%
1日の値動き範囲:
$16.46
$16.66
1週間の範囲:
$15.98
$16.76
52週間の値動き範囲:
$12.99
$18.89
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
16.58 | 52.36B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.20 | 40.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.92 | 32.58B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
566.80 | 24.07B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-08 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | 再開されました | Morgan Stanley | Overweight |
| 2025-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
Jury Hits Takeda With $885 Million Antitrust Verdict - Benzinga
Takeda Pharmaceutical stock (JP3730800003): earnings in focus as investors weigh legal risks - AD HOC NEWS
Takeda Pharmaceutical stock (JP3730800003): recent earnings and Rybelsus biosimilar plans in focus - AD HOC NEWS
Takeda Pharmaceutical Co Ltd stock (JP3730800003): earnings beat but softer EPS outlook - AD HOC NEWS
TAK Stock Price, Quote & Chart | TAKEDA PHARMACEUTIC-SP ADR (NYSE:TAK) - ChartMill
Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline - Morningstar
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 By Investing.com - Investing.com Australia
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 - Investing.com
Takeda Pharmaceutical stock (JP3730800003): FY2026 profit surges 77.7%, but FY2027 guidance signals - AD HOC NEWS
Takeda Pharma ADR earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
Takeda Surpasses Earnings Estimates Despite Revenue Miss - HarianBasis.co
What's Going On With Takeda Stock Wednesday?Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga
Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience - Investing.com
Takeda Pharmaceutical stock (JP3730800003): Q4 2026 earnings report released - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (FRA:TKDA) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd stock (JP3730800003): Is its rare disease focus strong enough to unlock - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock News, Headlines & Updates - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Baskets - GuruFocus
Takeda Pharmaceutical (ADR) stock (US8740602052): Why Google Discover changes matter more now - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Competitors 2026 - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Operating Data - GuruFocus
Takeda Pharmaceutical Co Ltd stock: What you should know now for smart investing - AD HOC NEWS
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Benzinga
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Takeda Pharmaceutical (ADR) Stock: A Stable Global Pharma Play with Focus on Oncology and Rare Disea - AD HOC NEWS
Who's Buying or Selling Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock Today? - gurufocus.com
Takeda Pharmaceutical Co Ltd Stock Intrinsic Values | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Historical Valuations | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd (LTS:0A87) Bonds - GuruFocus
Takeda Pharmaceutical stock faces pressure from geopolitical risks amid pipeline advances - AD HOC NEWS
Takeda Pharmaceutical (ADR) stock faces pressure amid pipeline setbacks and competitive oncology cha - AD HOC NEWS
Takeda: 'Hold' Despite Performance In 2025-2026 (NYSE:TAK) - Seeking Alpha
Takeda Pharmaceutical (ADR) Stock Steady Amid Pharma Sector Volatility as Investors Eye Pipeline Pro - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA)Valuation Measures & Financial Statistics - GuruFocus
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Takeda Stock: Quiet Japan Pharma With a Big U.S. Pipeline Bet - AD HOC NEWS
Takeda Stock: Quiet Pharma Giant That US Investors Keep Missing - AD HOC NEWS
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
0.33%
0.03%
大文字化:
|
ボリューム (24 時間):